ArticleRadiation oncology (London, England)2026
Radiation-induced hepatic toxicity from radiotherapy plus immune checkpoint inhibitors with targeted therapy in HCC patients: a propensity score-matched study.
Article in Radiation oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
purposeThis aim of the study was to compare the outcomes of radiation-induced hepatic toxicity (RIHT) of hepatocellular carcinoma (HCC) patients treated with radiotherapy (RT) combined with immune checkpoint inhibitors (ICIs) and targeted therapy with those of RT alone or RT combined with ICIs.
methodsA total of 146 patients with HCC who received RT between January 2017, and May 2023 were enrolled in the study; 50 and 96 patients received a combination of RT with ICIs plus targeted therapy (triple therapy), and RT alone or RT plus ICIs (RT/RT+ICIs), respectively. Propensity-score matched (PSM) analyses were performed to compare the hepatotoxicity, dosimetric, and clinical parameters between the groups. Non-classical radiation-induced liver disease (ncRILD) was evaluated using univariate and multivariate analyses.
resultsAfter matching, 50 patients were included per group. The ncRILD rates were 16.0% in the triple therapy group and 18.0% in the RT/RT+ICIs group, respectively (p = 0.790). Increased Child-Pugh (CP) scores ≥ 2 were observed in 16.0% each of the triple therapy and RT/RT+ICIs groups (p = 1.000). Increased CP scores ≥ 1 were observed in 38.0% and 40.0% of the triple therapy and RT/RT+ICIs groups, respectively (p = 0.838). The groups did not differ significantly in all hepatotoxicity metrics after PSM (p > 0.05). Normal liver volume (Vliver) was an independent predictor of ncRILD in the matched cohort.
conclusionsRT in combination with ICIs and targeted therapy is a seemingly safe treatment modality and achieves comparable RIHT with RT/RT+ICIs in HCC patients. Higher Vliver values indicate lower risks of developing ncRILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.